Research On The Optimization Of The Main Body Of Drug Governance In My Country

Drugs are used to prevent,treat,and diagnose human diseases,purposefully regulate human physiology and regulate substances with indications or functional indications,usage,and dosage.The safety of drugs has been closely watched by the government and the public.However,under such strict control,various problems still occur,because the wrong storage method,improper use,and exaggerated false advertising and publicity have made medicines originally used to cure diseases and save people a threat to the lives of the public.Relying solely on government supervision has been unable to cope with the increasingly difficult drug safety issues.It has become a hot topic to discuss the introduction of other parties to participate in drug governance.With the in-depth development of social governance theoretical research in China,multiple subjects such as governments,social organizations,enterprises,institutions and individuals actively participate in social life in various ways and ultimately maximize the public interest.The problem of drug safety has become a serious problem that needs to be solved urgently in my country for a long time in the future,and the community has given high attention to the problem of drug safety.my country has continuously improved and optimized the types and participation methods of drug governance subjects.Although some results have been achieved,there are still many areas for improvement.Either there will be no safety incidents in the pharmaceutical field.Once it occurs,it will be a major incident involving a wide range of people,and it must be strictly guarded against and cracked down.It must be pre-judged in advance,and the risk should be choked in the cradle.Local risks may turn into large risks,comprehensive risks,and systemic risks.We insist on the party' s leadership not being relaxed,unite all forces that can be united,and exert the wisdom of the masses to strive for innovation and jointly meet various challenges.This has important guiding significance for the development of this study.This article focuses on the main body of drug supervision and then turns into the main body of drug governance,combined with the current legislation,selects the perspective of the historical evolution of China's drug regulatory system,points out the status quo and problems of the main body of drug governance in China,and treats China's drugs with the United States,the European Union and Japan.Comparing the regulatory system,regulatory subjects and their functional means,and drawing on the experience of developed countries,they put forward suggestions that are in line with the optimization of China's drug governance subjects.This article mainly includes the following four parts.The first part is to explain the concept of the main body of drug governance,mainly introduces the related concepts of "drug","governance" and"subject",and refines the classification of multiple subjects,their respective positions and functions,The study analyzes the importance of the diversification of drug governance subjects of drug safety,and concludes that China should continue to optimize the goal of drug governance subjects.The second part analyzes the current situation and problems of the main body of drug administration in China.It is carried out from the current legislative requirements,mainly in conjunction with the relevant legal provisions of the "Pharmaceutical Administration Law of the People's Republic of China","Administrative Measures for Drug Production Supervision"and "Administrative Measures for Drug Registration" Analysis;the evolution and regulatory effects of the drug regulatory department are roughly divided into four parts in chronological order for discussion;the current status of corporate,social and citizen participation in governance is explained by interpreting the contents of the three social governance blue book reports.From the perspectives of insufficient government supervision power,lack of professionalization of law enforcement personnel;companies failing to recognize corporate social responsibility and fail to establish correct corporate values;social public participation is limited in governance,lack of clear and specific regulations on participation rights.The problems existing in the main body of drug management are analyzed at multiple levels.The third part is a comparative analysis of the similarities and differences between government regulatory,corporate self-regulatory,industry association monitoring and public participation,and draws on the experience of drug multi-agent governance in the United States,the European Union,and Japan,mainly from improving drug supervision.The legal system,the establishment of an advanced drug regulatory personnel training system,the guarantee of efficient drug regulatory agency functions,and the realization of multiple governance subjects participating in drug governance are summarized to find out the reference for optimizing the drug governance subjects in China.The fourth part analyzes the role relationship between the various subjects,proposes countermeasures for optimizing the main body of drug administration in China,and makes reference suggestions from the perspectives of perfecting legislation,improving government supervision and law enforcement,and strengthening the joint governance of multiple subjects,so as to realize the main body of drug administration The ideal goal of diversification is to better promote and improve the construction of pharmaceutical governance system and contribute to the development of the medical and health undertakings of China.